What is everyone's assessment of pyrilutamide 1.0% topical as a adjunct treatment?
    Research/Science 6/16/2026

    View this post in the Community →

    Similar Community Posts Join

    5 / 1000+ results

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  133 upvotes 2 years ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community No side effects on pyrilutamide / KX-826 so far

      in Research/Science  207 upvotes 4 years ago
      User TopBack56 and friends tried pyrilutamide (KX-826) for hair loss without experiencing negative side effects. They observed fine vellus hairs but no thick hair growth yet, and plan to add GT20029 to their regime after safety trials.

      community Dutasteride 1 year regression. Depressing. (With pictures for proof)

      in Progress Pictures  14 upvotes 2 years ago
      A user shared their experience of hair loss progression after one year on dutasteride, expressing disappointment with no improvement and considering other treatments like RU58841. Other users offered mixed responses, some seeing no change, others suggesting the hair loss might have been worse without treatment, and discussing the role of testosterone and DHT in hair loss.

      community Pyrilutamide Phase 3 on its way

      in Treatment  125 upvotes 4 years ago
      Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.

    Related Research

    6 / 1000+ results